Nyxoah Full Year 2024 Earnings: Misses Expectations

Simply Wall St

March 14, 2025

Nyxoah (EBR:NYXH) Full Year 2024 Results

Key Financial Results

Net loss: €59.2m (loss widened by 37% from FY 2023).
€1.81 loss per share (further deteriorated from €1.55 loss in FY 2023).

earnings-and-revenue-growth — ENXTBR:NYXH Earnings and Revenue Growth March 14th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nyxoah Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 8.0%.

Looking ahead, revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 7.2% growth forecast for the Medical Equipment industry in Europe.

Performance of the market in Belgium.

The company's shares are up 3.6% from a week ago.

Risk Analysis

It is worth noting though that we have found 5 warning signs for Nyxoah (2 can't be ignored!) that you need to take into consideration.

If you're looking to trade Nyxoah, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Valuation is complex, but we're here to simplify it.

Discover if Nyxoah might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.